Opus GeneticsIRD +1.48%24 3-Year ROIIC % is 1,683.34 as of Dec. 2025, which is 174% above its 10-year median of 613.66. GuruFocus rates IRD with a GF Score™ of 24/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,323 Biotechnology companies, Opus Genetics ranks better than 95.62% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Opus Genetics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 1,683.34%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Opus Genetics's 3-Year ROIIC % or its related term are showing as below:
IRD's 3-Year ROIIC % is ranked better than 95.62% of 1323
companies
in the Biotechnology industry
Industry Median: -4.82
vs IRD: 1683.34
Opus Genetics (NAS:IRD) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Opus Genetics 3-Year ROIIC % Related Terms
Opus Genetics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Opus Genetics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IRD vs PALI, VSTM, GALT: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Opus Genetics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Opus Genetics's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Opus Genetics (IRD) has a 3-Year ROIIC % of 1,683.34 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Opus Genetics and its competitors. This is 174% above median its historical median of 613.66. According to the industry distribution chart, Opus Genetics ranks #58 out of 1323 companies in the Biotechnology industry, placing it in the top 4.4%.
Is Opus Genetics' 3-Year ROIIC % too high?
Opus Genetics' current 3-Year ROIIC % of 1,683.34 is 174% above median its 10-year median of 613.66. Based on the distribution chart, Opus Genetics ranks #58 out of 1323 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Opus Genetics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' 3-Year ROIIC % compare to PALI and VSTM?
According to the Biotechnology industry distribution chart, Opus Genetics ranks #58 out of 1323 companies for 3-Year ROIIC %. This places Opus Genetics in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Opus Genetics and its competitors. Opus Genetics's current 3-Year ROIIC % is 1,683.34, which is 174% above median its own 10-year median of 613.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $4.11 — trading 1010.8% above its estimated fair value. The current 3-Year ROIIC % is 1,683.34, which is 174% above median its 10-year median of 613.66. Opus Genetics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Opus Genetics (IRD), the current 3-Year ROIIC % is 1,683.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Opus Genetics (IRD) Overvalued in 2026?
Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued.
The current stock price of $4.11 is trading 1010.8% above its estimated GF Value™ of $0.37.
GuruFocus considers Opus Genetics to be Significantly Overvalued.
Key valuation signals for IRD:
3-Year ROIIC %: 1,683.34 (174% above median its 10-year median of 613.66)
GF Value™: $0.37 vs. price of $4.11 (1010.8% above fair value)
No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
24GF Score
Get the complete analysis for IRD
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRD has been successfully added to your 
